Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

Tirzepatide’s dual effects on GLP-1 and GIP may explain its superior performance over semaglutide, the active ingredient in Wegovy. Lack of insurance coverage and high costs remain a barrier to ...

Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed ...

And one clearly comes out on top. Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized weight loss. But, strangely, no one has compared the ...

Adults receiving tirzepatide lost more weight and had a ... 10% or 15% of their body weight than those using semaglutide (Wegovy, Novo Nordisk). Similar findings were observed in the SURMOUNT ...

A new study led by Weill Cornell Medicine researchers reveals that tirzepatide (Mounjaro, Zepbound) helps people lose significantly more weight than semaglutide (Wegovy). The difference is ...

A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about ... the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have demonstrated clinically ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

None had diabetes, The Associated Press reported. Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.